Related Experiment Video
Updated: Oct 21, 2025
03:13
Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
Published on: November 3, 2023
2.5K
Prussian blue-based theranostics for ameliorating acute kidney injury
Dong-Yang Zhang1,2, Hengke Liu1, Kathy S Zhu1,3
1Marshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, 518060, China.
Journal of Nanobiotechnology
|September 7, 2021
Summary
Ultrasmall Prussian blue nanozymes (PB NZs) effectively eliminate reactive oxygen/nitrogen species (RONS) to treat acute kidney injury (AKI). These nanozyme theranostics offer dual-modal imaging guidance for enhanced AKI management.
Area of Science:
- Nanomedicine
- Biomedical Engineering
- Materials Science
Background:
- Acute kidney injury (AKI) is a critical condition with high mortality, often exacerbated by excessive reactive oxygen/nitrogen species (RONS).
- Nanomedicine offers a promising avenue for antioxidant therapy in AKI treatment.
- Ultrasmall Prussian blue nanozymes (PB NZs) were developed as theranostic agents.
Purpose of the Study:
- To synthesize and evaluate ultrasmall Prussian blue nanozymes (PB NZs) for dual-modal imaging-guided treatment of AKI.
- To investigate the antioxidant and therapeutic capabilities of PB NZs in AKI models.
Main Methods:
- Synthesis of ultrasmall Prussian blue nanozymes (4.5 nm).
- Evaluation of multi-enzyme mimetic abilities for RONS elimination in vitro and in vivo.
- Utilized magnetic resonance (MR)/photoacoustic (PA) dual-modal imaging to track renal accumulation of PB NZs.
- Assessed therapeutic efficacy in clinically relevant murine models of AKI induced by rhabdomyolysis and cisplatin.
Main Results:
- PB NZs demonstrated potent in vitro and in vivo RONS elimination via multi-enzyme mimetic activities.
- Dual-modal PA/MR imaging confirmed rapid renal accumulation of PB NZs.
- Ultrasmall PB NZs showed superior efficacy in treating AKI compared to amifostine in established murine models.
Conclusions:
- Ultrasmall Prussian blue nanozymes function as effective nanozyme theranostics.
- PB NZs hold significant potential for the clinical management of acute kidney injury.
Related Concept Videos
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
92
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
92
01:20Acute Kidney Injury V: Interprofessional Care
78
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
78
01:22Acute Kidney Injury I: Introduction
180
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
180
01:29Acute Kidney Injury II: Pathophysiology
306
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
306
01:22Acute Kidney Injury VI: Nursing Management
125
Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
125
01:29Acute Kidney Injury III: Clinical Manifestations
289
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
289